Edgar Filing: SUVARI TRICIA BORGA - Form 5

SUVARI TRICIA BORGA

Form 5

February 14, 2018

FORN	1 15								OIVID AF	PROVAL		
. •		STATES	SECUE	RITIES AN	D EXCH	IAN	GE CO	MMISSION	OMB Number:	3235-0362		
no longer	Check this box if washington, D.C. 20549 no longer subject							Expires:	January 31 2005			
Form 4 o 5 obligati may cont	Tomi Torrom				ENT OF CHANGES IN BENEFICIAL RSHIP OF SECURITIES				Estimated average burden hours per response 1.			
See Instru 1(b). Form 3 H Reported Form 4 Transacti Reported	Filed purs Ioldings Section 17(a	a) of the l	Public U		g Compa	any A	Act of 1	Act of 1934, 935 or Section	1			
SUVARI TRICIA BORGA Symbol				Name and Ticker or Trading Blood Therapeutics, Inc.				5. Relationship of Reporting Person(s) to Issuer				
			[GBT]						ck all applicable)			
(Last)	(First) (M	12/31/2017 below)				e title 10% Owner Other (specify below)						
THERAPE	SAL BLOOD UTICS, INC., 1 POINT BLVD., SU							Cniei	Legal Officer			
	(Street) 4. If Amendment, Date Original 6. Individu Filed(Month/Day/Year)					or Joint/Group Reporting						
SOUTH SA	ΔN											
FRANCISCO, CA 94080					_X_ Form Filed by One Reporting Person Form Filed by More than One Reporting Person							
(City)	(State)	(Zip)	Tabl	e I - Non-Der	ivative Sec	curitie	es Acqui	red, Disposed of,	or Beneficiall	y Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deen Execution any (Month/E	Date, if	3. Transaction Code (Instr. 8)	4. Securities Acquired 5. (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) (A) (A) (C) (C		5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	07/31/2017	Â		A4	Amount 666 (1)	(D) A	Price \$ 13.69	666	D	Â		
	port on a separate line eficially owned directly			contained i	n this for	m are	e not re	ection of inform quired to respondid OMB control	nd unless	SEC 2270 (9-02		

Edgar Filing: SUVARI TRICIA BORGA - Form 5

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	le and	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	Number	Expiration D	ate	Amou	ınt of	Derivative
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	rlying	Security
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)
	Derivative				Securities			(Instr.	3 and 4)	
	Security				Acquired					
					(A) or					
					Disposed					
					of (D)					
					(Instr. 3,					
					4, and 5)					
									Amount	
									or	
						Date Exercisable	Expiration Date	Title	Number	
									of	
					(A) (D)				Shares	

Relationshine

of D

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SUVARI TRICIA BORGA							
C/O GLOBAL BLOOD THERAPEUTICS, INC.	â	â	Chief Legal Officer	â			
171 OYSTER POINT BLVD., SUITE 300	А	A	A Ciliei Legai Officei	A			
SOUTH SAN FRANCISCO, CA 94080							

Signatures

/s/ Lesley Calhoun as Attorney-in-Fact for the Reporting
Person 02/14/2018

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2